{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:13Z","timestamp":1792787953487,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research grant from the Convergence Medical Institute, Pusan National University Hospital","award":["Project No. CMIT2026-04"],"award-info":[{"award-number":["Project No. CMIT2026-04"]}],"id":[{"id":"https:\/\/ror.org\/027zf7h57","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) are associated with adverse vascular events, including cerebrovascular stenosis. However, most reported cases rely on luminal imaging, and the arterial wall characteristics of TKI-associated vasculopathy remain insufficiently characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 47-year-old man with chronic myeloid leukemia developed recurrent transient ischemic attacks during long-term exposure to multiple tyrosine kinase inhibitors, including sequential treatment with nilotinib and ponatinib. Neurovascular imaging revealed extensive multifocal steno-occlusive lesions involving both intracranial and extracranial arteries, accompanied by severe hemodynamic compromise. High-resolution vessel wall MRI demonstrated diffuse circumferential wall thickening with negative remodeling in both distal internal carotid arteries and eccentric thickening along the anterior walls of the bilateral M1 segments of the middle cerebral artery. Notably, no definite mural enhancement was observed. Following discontinuation of ponatinib and transition to alternative therapy, cerebral perfusion improved at two months, and the patient remained clinically stable without recurrent ischemic events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case illustrates a potentially distinct vessel wall thickening pattern in TKI-associated vasculopathy, providing information beyond luminal stenosis. The absence of definite mural enhancement and clinical and hemodynamic improvement after treatment modification suggest a drug-related vascular component. Vessel wall imaging may aid in the evaluation of this condition and inform management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05192-x","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:05:04Z","timestamp":1784538304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tyrosine kinase inhibitor\u2013associated cerebral vasculopathy with a distinct non-enhancing vessel wall phenotype: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Jeong Eun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8884-4114","authenticated-orcid":false,"given":"Jaeseob","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"5192_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"key":"5192_CR2","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457\u201367. https:\/\/doi.org\/10.1056\/NEJMra1100265.","journal-title":"N Engl J Med"},{"key":"5192_CR3","doi-asserted-by":"publisher","first-page":"1367869","DOI":"10.3389\/fstro.2024.1367869","volume":"3","author":"A Hanazono","year":"2024","unstructured":"Hanazono A, Abe M, Togashi S, Takahashi T, Takahashi N, Sugawara M. Case report: three characteristics of tyrosine kinase inhibitor-associated cerebrovascular stenosis. High threshold for infarction, atypical infarct area, and vascular recoverability under the use of ponatinib. Front Stroke. 2024;3:1367869. https:\/\/doi.org\/10.3389\/fstro.2024.1367869.","journal-title":"Front Stroke"},{"key":"5192_CR4","doi-asserted-by":"publisher","first-page":"1871606","DOI":"10.1155\/crnm\/1871606","volume":"2025","author":"E Papatolis","year":"2025","unstructured":"Papatolis E, Kalampokini S, Liouta E, et al. Tyrosine kinase inhibitors as risk factors for cerebral vascular disease: report of two cases and literature review. Case Rep Neurol Med. 2025;2025:1871606. https:\/\/doi.org\/10.1155\/crnm\/1871606.","journal-title":"Case Rep Neurol Med"},{"key":"5192_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12883-024-04006-2","volume":"25","author":"N Sasaki","year":"2025","unstructured":"Sasaki N, Enomoto Y, Hori T, Matsubara H, Egashira Y, Izumo T. Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases. BMC Neurol. 2025;25:6. https:\/\/doi.org\/10.1186\/s12883-024-04006-2.","journal-title":"BMC Neurol"},{"key":"5192_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3892\/mco.2018.1780","volume":"10","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Yamamoto J, Kakeda S, et al. Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: a case report. Mol Clin Oncol. 2019;10:239\u201343. https:\/\/doi.org\/10.3892\/mco.2018.1780.","journal-title":"Mol Clin Oncol"},{"key":"5192_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/jha2.775","volume":"4","author":"DG Corr\u00eaa","year":"2023","unstructured":"Corr\u00eaa DG, Dos Santos RQ, Hygino da Cruz LC Jr. Contribution of intracranial vessel wall magnetic resonance imaging in nilotinib-associated vascular adverse effects diagnosis. EJHaem. 2023;4:1164\u20135. https:\/\/doi.org\/10.1002\/jha2.775.","journal-title":"EJHaem"},{"key":"5192_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2176\/jns-nmc.2022-0298","volume":"10","author":"Y Rai","year":"2023","unstructured":"Rai Y, Hara T. Tyrosine kinase inhibitor-associated cerebral arterial occlusive disease treated with high-flow bypass surgery: a case report. NMC Case Rep J. 2023;10:61\u20136. https:\/\/doi.org\/10.2176\/jns-nmc.2022-0298.","journal-title":"NMC Case Rep J"},{"key":"5192_CR9","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1161\/STROKEAHA.117.018227","volume":"48","author":"M Mossa-Basha","year":"2017","unstructured":"Mossa-Basha M, Shibata DK, Hallam DK, et al. Added value of vessel wall magnetic resonance imaging for differentiation of nonocclusive intracranial vasculopathies. Stroke. 2017;48:3026\u201333. https:\/\/doi.org\/10.1161\/STROKEAHA.117.018227.","journal-title":"Stroke"},{"key":"5192_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3174\/ajnr.A4893","volume":"38","author":"DM Mandell","year":"2017","unstructured":"Mandell DM, Mossa-Basha M, Qiao Y, et al. Intracranial vessel wall MRI: principles and expert consensus recommendations of the American Society of Neuroradiology. AJNR Am J Neuroradiol. 2017;38:218\u201329. https:\/\/doi.org\/10.3174\/ajnr.A4893.","journal-title":"AJNR Am J Neuroradiol"},{"key":"5192_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent P, Hadzijusufovic E, Hoermann G, F\u00fcreder W, Schernthaner GH, Sperr WR, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47\u201354. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.008.","journal-title":"Leuk Res"},{"key":"5192_CR12","doi-asserted-by":"publisher","first-page":"e0294438","DOI":"10.1371\/journal.pone.0294438","volume":"18","author":"Y Wang","year":"2023","unstructured":"Wang Y, Travers RJ, Farrell A, et al. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors. PLoS One. 2023;18:e0294438. https:\/\/doi.org\/10.1371\/journal.pone.0294438.","journal-title":"PLoS One"},{"key":"5192_CR13","doi-asserted-by":"publisher","first-page":"e72952","DOI":"10.7759\/cureus.72952","volume":"16","author":"S Sibal","year":"2024","unstructured":"Sibal S, Patankar A, Raut T. Nilotinib as an independent risk factor for stroke by accelerated atherosclerosis. Cureus. 2024;16:e72952. https:\/\/doi.org\/10.7759\/cureus.72952.","journal-title":"Cureus"},{"key":"5192_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.125.073610","volume":"152","author":"A Stepanian","year":"2025","unstructured":"Stepanian A, Travers RJ, Tesfu A, et al. Ponatinib, but not the new Abl-kinase inhibitor asciminib, activates platelets, leukocytes, and endothelial cell TNF signaling to induce atherosclerotic plaque inflammation, myocardial infarction, and stroke. Circulation. 2025;152:765\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.073610.","journal-title":"Circulation"},{"key":"5192_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","volume":"41","author":"MD Wu","year":"2021","unstructured":"Wu MD, Moslehi JJ, Lindner JR. Arterial thrombotic complications of tyrosine kinase inhibitors. Arterioscler Thromb Vasc Biol. 2021;41:3\u201310. https:\/\/doi.org\/10.1161\/ATVBAHA.120.314694.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05192-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:01:55Z","timestamp":1791997315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05192-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5192"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05192-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication, including the use of anonymized clinical information and imaging data, was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"651"}}